Advertisement
Advertisement
NPCE
Neuropace, Inc. Common Stock
15.79
USDSponsored
+0.30
+1.94%
Feb 06, 14:10 UTC -5
Closed
After-Market
15.79
0.00
0.00%
NPCE Earnings Reports
Positive Surprise Ratio
NPCE beat 12 of 19 last estimates.
63%
Next Report
Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$25.73M
/-$0.14
Implied change from Q3 25 (Revenue/ EPS)
-5.92%
/+27.27%
Implied change from Q4 24 (Revenue/ EPS)
+19.88%
/-22.22%
Neuropace, Inc. Common Stock earnings per share and revenue
On Nov 04, 2025, NPCE reported earnings of -0.11 USD per share (EPS) for Q3 25, beating the estimate of -0.20 USD, resulting in a 45.05% surprise. Revenue reached 27.35 million, compared to an expected 25.13 million, with a 8.86% difference. The market reacted with a +38.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.14 USD, with revenue projected to reach 25.73 million USD, implying an increase of 27.27% EPS, and decrease of -5.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Mesa Laboratories Inc
Report Date
Feb 03, 2026 For Q3 26
Estimate
$0.28
Actual
$3.07
Surprise
+987.88%
Accuray Incorporated
Report Date
Feb 04, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+1.96%
Thermo Fisher Scientific, Inc.
Report Date
Jan 29, 2026 For Q4 25
Estimate
$6.51
Actual
$6.57
Surprise
+0.91%
Idexx Laboratories Inc
Report Date
Feb 02, 2026 For Q4 25
Estimate
$2.98
Actual
$3.08
Surprise
+3.12%
IQVIA Holdings Inc.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$3.43
Actual
$3.42
Surprise
-0.34%
Mettler-Toledo International
Report Date
Feb 05, 2026 For Q4 25
Estimate
$12.92
Actual
$13.36
Surprise
+3.34%
STERIS plc
Report Date
Feb 04, 2026 For Q3 26
Estimate
$2.55
Actual
$2.52
Surprise
-0.99%
Hologic Inc
Report Date
Jan 29, 2026 For Q1 26
Estimate
$1.11
Actual
$1.04
Surprise
-6.45%
FAQ
What were Neuropace, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Neuropace, Inc. Common Stock reported EPS of -$0.11, beating estimates by 45.05%, and revenue of $27.35M, 8.86% above expectations.
How did the market react to Neuropace, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 38.09%, changed from $9.40 before the earnings release to $12.98 the day after.
When is Neuropace, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for Neuropace, Inc. Common Stock's next earnings report?
Based on 10
analysts, Neuropace, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of $25.73M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement